Inherited platelet disorders: Toward DNA-based diagnosis

Blood

Volumn 127, Issue 23, 2016, Pages 2814-2823

  Lentaigne, Claire ^a,b   Freson, Kathleen ^c   Laffan, Michael A ^a,b   Turro, Ernest ^d,e,f,g   Ouwehand, Willem H ^d,e,g,h  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e NHS BLOOD AND TRANSPLANT   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; THROMBOXANE;

ARTICLE; BLEEDING; CLINICAL FEATURE; CYTOLOGY; DATA BASE; DISEASE SEVERITY; DNA DETERMINATION; DNA INTEGRATION; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE ONTOLOGY; GENE SEQUENCE; GENETIC CODE; GENETIC HETEROGENEITY; GENETIC TRAIT; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; GLANZMANN DISEASE; HIGH THROUGHPUT SEQUENCING; HISTOPATHOLOGY; HUMAN; INHERITANCE; INHERITED PLATELET DISORDER; MEGAKARYOPOIESIS; NONHUMAN; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; RISK FACTOR; STANDARD; THROMBOCYTE; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; BLOOD; BLOOD PLATELET DISORDERS; GENETICS; MOLECULAR DIAGNOSIS; PHYSIOLOGY; PROCEDURES; RARE DISEASES; TRENDS;

BLOOD PLATELET DISORDERS; BLOOD PLATELETS; DNA; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; RARE DISEASES; THROMBOPOIESIS;

EID: 84974569548     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-378588     Document Type: Article

References (120)

1. Gieger C, Radhakrishnan A, Cvejic A, et al. New gene functions in megakaryopoiesis and platelet formation. Nature. 2011;480(7376):201-208.
2. Westbury SK, Turro E, Greene D, et al; BRIDGE-BPD Consortium. Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. Genome Med. 2015;7(1):36.
3. Dasouki MJ, Rafi SK, Olm-Shipman AJ, et al. Exome sequencing reveals a thrombopoietin ligand mutation in a Micronesian family with autosomal recessive aplastic anemia. Blood. 2013;122(20):3440-3449.
4. Dasouki M, Roberts J, Santiago A, Saadi I, Hovanes K. Confirmation and further delineationof the 3q26.33-3q27.2 microdeletion syndrome.Eur J Med Genet. 2014;57(2-3):76-80.
5. Ihara K, Ishii E, Eguchi M, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA. 1999;96(6):3132-3136.
6. Savoia A, Dufour C, Locatelli F, et al. Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica. 2007;92(9):1186-1193.
7. Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet. 2000;24(3):266-270.
8. Yu C, Niakan KK, Matsushita M, Stamatoyannopoulos G, Orkin SH, Raskind WH. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1interaction. Blood. 2002;100(6):2040-2045.
9. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999; 23(2):166-175.
10. Hart A, Melet F, Grossfeld P, et al. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity. 2000; 13(2):167-177.
11. Noetzli L, Lo RW, Lee-Sherick AB, et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47(5):535-538.
12. Thompson AA, Nguyen LT. Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation. Nat Genet. 2000;26(4):397-398.
13. Niihori T, Ouchi-Uchiyama M, Sasahara Y, et al.Mutations in MECOM, Encoding Oncoprotein EVI1, Cause Radioulnar Synostosis with Amegakaryocytic Thrombocytopenia. Am J Hum Genet. 2015;97(6):848-854.
14. Stevenson WS, Morel-Kopp MC, Chen Q, et al. GFI1B mutation causes a bleeding disorder with abnormal platelet function. J Thromb Haemost. 2013;11(11):2039-2047.
15. Monteferrario D, Bolar NA, Marneth AE, et al. A dominant-negative GFI1B mutation in the gray platelet syndrome. N Engl J Med. 2014;370(3):245-253.
16. Albers CA, Paul DS, Schulze H, et al. Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complexsubunit RBM8A causes TAR syndrome. Nat Genet. 2012;44(4):435-439, S1-S2.
17. Pippucci T, Savoia A, Perrotta S, et al. Mutations in the 59 UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet. 2011;88(1):115-120.
18. Seri M, Cusano R, Gangarossa S, et al; The May-Heggllin/Fechtner Syndrome Consortium. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. Nat Genet. 2000;26(1):103-105.
19. Kunishima S, Okuno Y, Yoshida K, et al. ACTN1 mutations cause congenital macrothrombocytopenia. Am J Hum Genet. 2013;92(3):431-438.
20. Nurden P, Debili N, Coupry I, et al. Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood. 2011;118(22):5928-5937.
21. Kunishima S, Kobayashi R, Itoh TJ, Hamaguchi M, Saito H. Mutation of the beta1-tubulin gene associated with congenitalmacrothrombocytopenia affecting microtubule assembly. Blood. 2009;113(2):458-461.
22. Stritt S, Nurden P, Turro E, et al. A gain-offunction variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood. 2016;127(23):2903-2914.
23. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994;78(4):635-644.
24. Zhu Q, Zhang M, Blaese RM, et al. The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. Blood. 1995;86(10):3797-3804.
25. Albers CA, Cvejic A, Favier R, et al. Exomesequencing identifies NBEAL2 as the causativegene for gray platelet syndrome. Nat Genet. 2011;43(8):735-737.
26. Kahr WH, Hinckley J, Li L, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet. 2011;43(8): 738-740.
27. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet a-granules. Nat Genet. 2011;43(8): 732-734.
28. Castermans D, Volders K, Crepel A, et al. SCAMP5, NBEA and AMISYN: three candidate genes for autism involved in secretion of large dense-core vesicles. Hum Mol Genet. 2010; 19(7):1368-1378.
29. Gissen P, Johnson CA, Morgan NV, et al. Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, causearthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nat Genet. 2004;36(4):400-404.
30. Cullinane AR, Straatman-Iwanowska A, Zaucker A, et al. Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization. Nat Genet. 2010;42(4):303-312.
31. zur Stadt U, Rohr J, Seifert W, et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet. 2009;85(4):482-492.
32. Côte M, Ménager MM, Burgess A, et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest. 2009;119(12):3765-3773.
33. Barbosa MD, Barrat FJ, Tchernev VT, et al. Identification of mutations in two major mRNA isoforms of the Chediak-Higashi syndrome genein human and mouse. Hum Mol Genet. 1997; 6(7):1091-1098.
34. Oh J, Bailin T, Fukai K, et al. Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder of cytoplasmic organelles. Nat Genet. 1996;14(3):300-306.
35. Dell'Angelica EC, Shotelersuk V, Aguilar RC, Gahl WA, Bonifacino JS. Altered trafficking of lysosomal proteins in Hermansky-Pudlaksyndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol Cell. 1999;3(1):11-21.
36. Anikster Y, Huizing M, White J, et al. Mutation of a new gene causes a unique form of Hermansky- Pudlak syndrome in a genetic isolate of central Puerto Rico. Nat Genet. 2001;28(4):376-380.
37. Suzuki T, Li W, Zhang Q, et al. Hermansky- Pudlak syndrome is caused by mutations in HPS4, the human homolog of the mouse lightear gene. Nat Genet. 2002;30(3):321-324.
38. Li W, Zhang Q, Oiso N, et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet. 2003;35(1):84-89.
39. Zhang Q, Zhao B, Li W, et al. Ru2 and Ru encode mouse orthologs of the genes mutated in human Hermansky-Pudlak syndrome types 5 and 6. Nat Genet. 2003;33(2):145-153.
40. Morgan NV, Pasha S, Johnson CA, et al. A germline mutation in BLOC1S3/reduced pigmentation causes a novel variant of Hermansky-Pudlak syndrome (HPS8). Am J Hum Genet. 2006;78(1):160-166.
41. Cullinane AR, Curry JA, Carmona-Rivera C, et al. A BLOC-1 mutation screen reveals thatPLDN is mutated in Hermansky-Pudlak Syndrome type 9. Am J Hum Genet. 2011;88(6): 778-787.
42. Wright SD, Michaelides K, Johnson DJ, West NC, Tuddenham EG. Double heterozygosity for mutations in the platelet glycoprotein IX gene in three siblings with Bernard-Soulier syndrome. Blood. 1993;81(9):2339-2347.
43. Savoia A, Kunishima S, De Rocco D, et al. Spectrum of the mutations in Bernard-Soulier syndrome. Hum Mutat. 2014;35(9):1033-1045.
44. Newman PJ, Seligsohn U, Lyman S, Coller BS. The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci USA. 1991;88(8):3160-3164.
45. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011;118(23):5996-6005.
46. Miller JL, Cunningham D, Lyle VA, Finch CN. Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci USA. 1991;88(11):4761-4765.
47. Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE. Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences. J Clin Invest. 1991;87(4):1220-1226.
48. Turro E, Greene D, Wijgaerts A, et al; BRIDGE-BPD Consortium. A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies. Sci Transl Med. 2016;8(328):328ra30.
49. Morison IM, Cramer Bordé EM, Cheesman EJ, et al. A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia. Nat Genet. 2008; 40(4):387-389.
50. Misceo D, Holmgren A, Louch WE, et al. A dominant STIM1 mutation causes Stormorken syndrome. Hum Mutat. 2014;35(5):556-564.
51. Nesin V, Wiley G, Kousi M, et al. Activating mutations in STIM1 and ORAI1 cause overlapping syndromes of tubular myopathy and congenital miosis. Proc Natl Acad Sci USA. 2014;111(11):4197-4202.
52. Lacruz RS, Feske S. Diseases caused bymutations in ORAI1 and STIM1. Ann N Y Acad Sci. 2015;1356:45-79.
53. Fletcher SJ, Johnson B, Lowe GC, et al; UK Genotyping and Phenotyping of Platelets study group. SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects. J Clin Invest. 2015; 125(9):3600-3605.
54. Marconi C, Di Buduo CA, Barozzi S, et al.SLFN14-related thrombocytopenia: identification within a large series of patients with inherited thrombocytopenia. Thromb Haemost. 2016; 115(5).
55. Paterson AD, Rommens JM, Bharaj B, et al. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood. 2010;115(6): 1264-1266.
56. Dumont B, Lasne D, Rothschild C, et al. Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations. Blood. 2009;114(9):1900-1903.
57. Fang J, Nurden P, North P, et al. C560Rb3 caused platelet integrin aII b b3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality. J Thromb Haemost. 2013;11(6):1163-1171.
58. Ghevaert C, Salsmann A, Watkins NA, et al. A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation andmacrothrombocytopenia. Blood. 2008;111(7): 3407-3414.
59. Svensson L, Howarth K, McDowall A, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med. 2009;15(3):306-312.
60. Canault M, Ghalloussi D, Grosdidier C, et al. Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding. J Exp Med. 2014;211(7): 1349-1362.
61. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001; 409(6817):202-207.
62. Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest. 1994; 94(4):1662-1667.
63. Geneviève D, Proulle V, Isidor B, et al.Thromboxane synthase mutations in anincreased bone density disorder (Ghosal syndrome). Nat Genet. 2008;40(3):284-286.
64. Adler DH, Cogan JD, Phillips JA III, et al. Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J Clin Invest. 2008;118(6): 2121-2131.
65. Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature. 2010;468(7325):834-838.
66. Gresele P; Subcommittee on Platelet Physiology of the International Society on Thrombosis and Hemostasis. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. J Thromb Haemost. 2015;13(2):314-322.
67. Bolton-Maggs PH, Chalmers EA, Collins PW, et al; UKHCDO. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol. 2006; 135(5):603-633.
68. Zhang MY, Churpek JE, Keel SB, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015; 47(2):180-185.
69. Noris P, Perrotta S, Seri M, et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood. 2011;117(24): 6673-6680.
70. Shin CR, Kim MO, Li D, et al. Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. Bone Marrow Transplant. 2012;47(11):1428-1435.
71. Hacein-Bey Abina S, Gaspar HB, Blondeau J, et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA. 2015;313(15):1550-1563.
72. Ballmaier M, Germeshausen M. Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. Semin Thromb Hemost. 2011;37(6):673-681.
73. Gresele P, Harrison P, Bury L, et al. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. J Thromb Haemost. 2014;12(9):1562-1569.
74. Quiroga T, Goycoolea M, Panes O, et al. Highprevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica. 2007;92(3): 357-365.
75. 12 receptor for adenosine diphosphate: congenital and druginduced defects. Blood. 2011;117(7):2102-2112.
76. Matus V, Valenzuela G, Sáez CG, et al. An adenine insertion in exon 6 of human GP6 generates a truncated protein associated with a bleeding disorder in four Chilean families. J Thromb Haemost. 2013;11(9):1751-1759.
77. Hermans C, Wittevrongel C, Thys C, Smethurst PA, Van Geet C, Freson K. A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder. J Thromb Haemost. 2009;7(8):1356-1363.
78. Mumford AD, Nisar S, Darnige L, et al; UK GAPP Study Group. Platelet dysfunction associated with the novel Trp29Cys thromboxane A? receptor variant. J Thromb Haemost. 2013; 11(3):547-554.
79. Zwaal RFA, Comfurius P, Bevers EM.Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta. 2004; 1636(2-3):119-128.
80. Bottega R, Marconi C, Faleschini M, et al. ACTN1-related thrombocytopenia: identification of novel families for phenotypic characterization. Blood. 2015;125(5):869-872.
81. Noris P, Favier R, Alessi MC, et al. ANKRD26- related thrombocytopenia and myeloid malignancies. Blood. 2013;122(11):1987-1989.
82. Simeoni I, Stephens JC, Hu F, et al. A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood. 2016;127(23): 2791-2803.
83. Peplow M. The 100 000 Genomes Project. BMJ. 2016;353(i1757):1-3.
84. Greene DNB, Richardson S, Turro E. Phenotype similarity regression for identifying the genetic determinants of rare diseases. Am J Hum Genet. 2016;98(3):490-499.
85. Mumford AD, Frelinger AL III, Gachet C, et al. A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders. Thromb Haemost. 2015;114(1):14-25.
86. Rao AK. Inherited platelet function disorders: overview and disorders of granules, secretion, and signal transduction. Hematol Oncol Clin North Am. 2013;27(3):585-611.
87. Watson SP, Lowe GC, Lordkipanidzé M, Morgan NV; GAPP consortium. Genotyping and phenotyping of platelet function disorders. J Thromb Haemost. 2013;11(Suppl 1):351-363.
88. Leo VC, Morgan NV, Bem D, et al; UK GAPP Study Group. Use of next-generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders. J Thromb Haemost. 2015;13(4):643-650.
89. Auton A, Brooks LD, Durbin RM, et al; 1000 Genomes Project Consortium. A globalreference for human genetic variation. Nature. 2015;526(7571):68-74.
90. Walter K, Min JL, Huang J, et al; UK10K Consortium. The UK10K project identifies rare variants in health and disease. Nature. 2015; 526(7571):82-90.
91. Exome Aggregation Consortium, Lek M, Karczewski K, et al. Analysis of protein-coding genetic variation in 60,706 humans [published online ahead of print October 30 2015]. BioRxiV. doi:10.1101/030338.
92. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifyingthe causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.
93. MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014;508(7497):469-476.
94. Landrum MJ, Lee JM, Benson M, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016; 44(D1):D862-D868.
95. Firth HV, Richards SM, Bevan AP, et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. Am J Hum Genet. 2009; 84(4):524-533.
96. Exome variant server. Available at: http://evs.gs.washington.edu/EVS/ Accessed 10 March, 2016.
97. Stenson PD, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet. 2014;133(1):1-9.
98. Xue Y, Chen Y, Ayub Q, et al; 1000 Genomes Project Consortium. Deleterious- and diseaseallele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. Am J Hum Genet. 2012;91(6):1022-1032.
99. Vidal M, Cusick ME, Barabási AL. Interactome networks and human disease. Cell. 2011;144(6): 986-998.
100. Rolland T, Taşan M, Charloteaux B, et al. A proteome-scale map of the human interactome network. Cell. 2014;159(5):1212-1226.
101. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74.
102. Kundaje A, Meuleman W, Ernst J, et al; Roadmap Epigenomics Consortium. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518(7539):317-330.
103. Chen L, Kostadima M, Martens JH, et al; BRIDGE Consortium. Transcriptional diversity during lineage commitment of human blood progenitors. Science. 2014;345(6204):1251033.
104. Köhler S, Doelken SC, Mungall CJ, et al. TheHuman Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Res. 2014; 42(Database issue):D966-D974.
105. Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature. 2015; 519(7542):223-228.
106. Masino AJ, Dechene ET, Dulik MC, et al. Clinical phenotype-based gene prioritization: an initial study using semantic similarity and the human phenotype ontology. BMC Bioinformatics. 2014; 15:248.
107. Zemojtel T, Köhler S, Mackenroth L, et al. Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome. Sci Transl Med. 2014;6(252):252ra123.
108. Bluteau D, Balduini A, Balayn N, et al. Thrombocytopenia-associated mutations in theANKRD26 regulatory region induce MAPK hyperactivation. J Clin Invest. 2014;124(2): 580-591.
109. Londin E, Loher P, Telonis AG, et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci USA. 2015; 112(10):E1106-E1115.
110. Tijssen MR, Cvejic A, Joshi A, et al. Genomewide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev Cell. 2011;20(5):597-609.
111. Vasquez LJ, Mann AL, Chen L, Soranzo N. From GWAS to function: lessons from blood cells. ISBT Sci Ser. 2016;11:211-219.
112. Freson K, De Vos R, Wittevrongel C, et al. The TUBB1 Q43P functional polymorphism reducesthe risk of cardiovascular disease in men by modulating platelet function and structure. Blood. 2005;106(7):2356-2362.
113. Auer PL, Teumer A, Schick U, et al. Rare and low-frequency coding variants in CXCR2 andother genes are associated with hematological traits. Nat Genet. 2014;46(6):629-634.
114. Kunishima S, Nishimura S, Suzuki H, Imaizumi M, Saito H. TUBB1 mutation disrupting microtubule assembly impairs proplatelet formation and results in congenital macrothrombocytopenia. Eur J Haematol. 2014; 92(4):276-282.
115. Jupe S, Akkerman JW, Soranzo N, Ouwehand WH. Reactome - a curated knowledgebase ofbiological pathways: megakaryocytes and platelets. J Thromb Haemost. 2012;10(11): 2399-2402.
116. Mumford AD, Dawood BB, Daly ME, et al. A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with ableedingdiathesis.Blood. 2010;115(2): 363-369.
117. Kamae T, Kiyomizu K, Nakazawa T, et al.Bleeding tendency and impaired platelet function in a patient carrying a heterozygous mutation in the thromboxane A2 receptor. J Thromb Haemost. 2011;9(5):1040-1048.
118. Nisar SP, Lordkipanidzé M, Jones ML, et al; UK GAPP study group. A novel thromboxane A2receptor N42S variant results in reduced surface expression and platelet dysfunction. Thromb Haemost. 2014;111(5):923-932.
119. Freson K, Thys C, van Geet C. First report of transheterozygosity in a patient with aninherited platelet bleeding disorder due to mutations in the Thromboxane A2 receptor (TBXA2R) and cyclooxygenase1 (PTGS1)[abstract]. Blood. 2011;118(21). Abstract 3260.
120. Hu Y, Yan C, Hsu CH, et al. OmicCircos: a simple-to-use R package for the circular visualization of multidimensional omics data. Cancer Inform. 2014;13:13-20.